Abstract: The present disclosure relates generally to the analysis of immune checkpoint proteins involved in cancer. In particular, the present disclosure provides material and methods for determining abundance ratios of various immune checkpoint proteins (e.g., PD-1, PD-L1, and PD-L2) present in a biospecimen sample based on quantification of peak area using mass spectrometry analysis. The methods disclosed herein provide an alternative platform for diagnosing and treating cancer, especially in cases limited by ineffective antibody recognition.

Abstract: Provided herein are methods for treating and preventing PD-1-mediated resistant cancers.

Abstract: A method of detecting cell membrane expression of an MHC molecule in a subject, a method of treating cancer in a subject with an immunotherapeutic agent, and an MHC complex are provided. The method of detecting cell membrane expression of an MHC molecule includes obtaining a tumor cell sample from a subject, and detecting cell membrane expression of the MHC molecule by contacting the tumor cell sample with an antibody targeting the MHC molecule and detecting binding between the MHC molecule and the antibody. The method of treating cancer in a subject with an immunotherapeutic agent includes detecting cell membrane expression of an MHC molecule in the subject and administering a therapeutically effective amount of the immunotherapeutic agent if the level of cell membrane expression of the MHC molecule exceeds a predetermined standard. The complex includes a tumor cell in complex with an antibody or an antigen-binding portion thereof.

Abstract: The presently-disclosed subject matter relates to methods and systems for examining tumor samples, methods and systems for identifying subjects who are likely responders to treatment, and methods for treating cancer. In some embodiments, the presently-disclosed subject matter relates to determining expression of a major histocompatibility complex-II (MHC-II) molecule on a cell from a tumor sample, and further involving determining presence of tumor-infiltrating T cells in the tumor sample, determining the presence of tumor-infiltrating lymphocytes in the tumor sample, detecting chemokine expression in the tumor sample, and/or detecting TP53 mutations in the tumor sample. In some embodiments, the method involves treatment with an immunotherapeutic agent either alone or in combination with an MDM2 antagonist or an MEK inhibitor.

Abstract: Dual sealing caps enclose, for example, a series of liquids to be combined to achieve desiderata of users. By providing, for example co-branded liquids such as an ethyl alcohol (Grey Goose® brand of vodka) and an energy drink (for example RGCKSTAR® brand or RED BULL® brand of energy drink), a fully loaded and pre-packaged bomb shot is offered for consideration according to the instant teachings. Likewise, modular and coaxial chamber sets that house substances to be at least temporarily separated are disclosed, taught (and available through Xtremco of Southern California) for housing of a multiplicity of substances, moieties and materials.

Abstract: The present disclosure relates generally to the analysis of immune checkpoint proteins involved in cancer. In particular, the present disclosure provides material and methods for determining abundance ratios of various immune checkpoint proteins (e.g., PD-1, PD-L1, and PD-L2) present in a biospecimen sample based on quantification of peak area using mass spectrometry analysis. The methods disclosed herein provide an alternative platform for diagnosing and treating cancer, especially in cases limited by ineffective antibody recognition.

Abstract: A method of detecting cell membrane expression of an MHC molecule in a subject, a method of treating cancer in a subject with an immunotherapeutic agent, and an MHC complex are provided. The method of detecting cell membrane expression of an MHC molecule includes obtaining a tumor cell sample from a subject, and detecting cell membrane expression of the MHC molecule by contacting the tumor cell sample with an antibody targeting the MHC molecule and detecting binding between the MHC molecule and the antibody. The method of treating cancer in a subject with an immunotherapeutic agent includes detecting cell membrane expression of an MHC molecule in the subject and administering a therapeutically effective amount of the immunotherapeutic agent if the level of cell membrane expression of the MHC molecule exceeds a predetermined standard. The complex includes a tumor cell in complex with an antibody or an antigen-binding portion thereof.

Abstract: An ultrasonic liquefaction endodontic system having a graspable hand piece includes a contra-angle tip assembly that has an insert and an internal fluid flow passageway. A portion of the fluid flow passageway passes through a C-shaped receiver located at the end of the receiver so that an ultrasonic frequency may pass directly to the fluid flowing through the passageway. The fluid flow passageway may be an injection tube and the tubular body portion of the tip assembly may be injection molded around the injection tube and the insert. A supply tube, which is held in position by tube guides connected to the hand piece, provides a source of flushing fluid with and without pulsed pressure. The fluid pressure pulses may have an ultrasonic energy superimposed thereon as the fluid is forced into a root canal.

Abstract: An ultrasonic liquefaction endodontic system having a graspable hand piece includes a contra-angle tip assembly that has an insert and an internal fluid flow passageway. A portion of the fluid flow passageway passes through a C-shaped receiver located at the end of the receiver so that an ultrasonic frequency may pass directly to the fluid flowing through the passageway. The fluid flow passageway may be an injection tube and the tubular body portion of the tip assembly may be injection molded around the injection tube and the insert. A supply tube, which is held in position by tube guides connected to the hand piece, provides a source of flushing fluid with and without pulsed pressure. The fluid pressure pulses may have an ultrasonic energy superimposed thereon as the fluid is forced into a root canal.

Abstract: An ultrasonic liquefaction endodontic system having a graspable hand piece includes a contra-angle tip assembly that has an insert and an internal fluid flow passageway. A portion of the fluid flow passageway passes through a C-shaped receiver located at the end of the receiver so that an ultrasonic frequency may pass directly to the fluid flowing through the passageway. The fluid flow passageway may be an injection tube and the tubular body portion of the tip assembly may be injection molded around the injection tube and the insert. A supply tube, which is held in position by tube guides connected to the hand piece, provides a source of flushing fluid with and without pulsed pressure. The fluid pressure pulses may have an ultrasonic energy superimposed thereon as the fluid is forced into a root canal.

Abstract: An ultrasonic liquefaction endodontic system having a graspable hand piece includes a contra-angle tip assembly that has an insert and an internal fluid flow passageway. A portion of the fluid flow passageway passes through a C-shaped receiver located at the end of the receiver so that an ultrasonic frequency may pass directly to the fluid flowing through the passageway. The fluid flow passageway may be an injection tube and the tubular body portion of the tip assembly may be injection molded around the injection tube and the insert. A supply tube, which is held in position by tube guides connected to the hand piece, provides a source of flushing fluid with and without pulsed pressure. The fluid pressure pulses may have an ultrasonic energy superimposed thereon as the fluid is forced into a root canal.

Abstract: Multilayer circuit devices include a plurality of metallized patterns thereon, said patterns being separated by a polymeric dielectric film. The various metallized patterns are interconnected by means of microvias through the polymeric film or films. Each of the metallizations is a composite including in succession from the substrate or from the polymeric film, a layer of titanium (Ti), a layer of titanium and palladium alloy (Ti/Pd), a layer of copper (Cu), and a layer of titanium and palladium alloy (Ti/Pd). The Ti-Ti/Pd-Cu-Ti/Pd composite is hereinafter referred to as TCT. The adhesion between the polymeric film and the top Ti/Pd layer is better than that between the polymer and gold (Au) and comparable to that between the polymer and an adhesion promoted Au layer. Use of the TCT metallization also results in additional cost reduction due to the elimination of Ni and Au layers on top of the Cu layer.

Abstract: Multilayer circuit devices include a plurality of metallized patterns thereon, said patterns being separated by a polymeric dielectric film. The various metallized patterns are interconnected by means of microvias through the polymeric film or films. Each of the metallizations is a composite including in succession from the substrate or from the polymeric film, a layer of titanium (Ti), a layer of titanium and palladium alloy (Ti/Pd), a layer of copper (Cu), and a layer of titanium and palladium alloy (Ti/Pd). The Ti--Ti/Pd--Cu--Ti/Pd composite is hereinafter referred to as TCT. The adhesion between the polymeric film and the top Ti/Pd layer is better than that between the polymer and gold (Au) and comparable to that between the polymer and an adhesion promoted Au layer. Use of the TCT metallization also results in additional cost reduction due to the elimination of Ni and Au layers on top of the Cu layer.